Noradrenergic Augmentation of SSRI [selective serotonin reuptake inhibitor] therapy in patients with depression unresponsive or incompletely responsive to SSRI monotherapy
Phase of Trial: Phase IV
Latest Information Update: 30 Jan 2010
At a glance
- Drugs Atomoxetine; Sertraline
- Indications Major depressive disorder
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Eli Lilly
- 31 Aug 2018 Biomarkers information updated
- 30 Jan 2010 Results were published in Psychiatry Research.
- 18 Jun 2007 New trial record.